


# New Strategies for Rapid <sup>18</sup>F-Radiolabeling of Biomolecules for Radionuclide-Based In Vivo Imaging

Jun-Liang Zeng,<sup>†</sup> Jian Wang,<sup>‡</sup> and Jun-An Ma\*,<sup>†</sup>

ABSTRACT: The increasing availability of highly active no-carrier-added [18F]fluoride makes its use in radiolabeling biomolecules attractive. By incorporating "fluorophilic" elements (Si, B, and Al) into biomolecules, recent advances offer mild and rapid <sup>18</sup>F-labeling approaches without HPLC purification at the radiosynthetic stage while maintaining sufficient specific activity. In this Topical Review, we will discuss the most recent strides in the field.



luorine-18 (18F) is the most widely used PET (positronemission tomography) radioisotope for clinical imaging because of its nearly ideal nuclear properties, including high positron emission abundance ( $\beta^+$ , 97%), low positron energy (0.635 MeV) resulting in limited positron migration (<2 mm), and suitable physical half-life (109.7 min). 1-5 Depending on the mode of production, no-carrier-added (NCA) [18F]fluoride ions can be readily obtained in an aqueous solution by proton irradiation of an [18O]-H2O target using a medical cyclotron (Figure 1, top). However, fluoride ions are very poorly nucleophilic in the presence of water. To improve its nucleophilicity, the [18F]-fluoride is commonly trapped on an anion exchange resin, eluted with a small volume of an organic-aqueous solution (e.g., CH<sub>3</sub>CN/H<sub>2</sub>O) of an inorganic base (potassium carbonate) and a cryptand (kryptofix: K 2.2.2) or tetrabutylammonium hydrogen carbonate (TBAHCO<sub>3</sub>). All water traces have to be removed by iterative azeotropic distillation, and the cryptand or ammonium enables solubilization of the [18F]-fluoride ion in a polar aprotic solvent suitable for the subsequent labeling reaction. However, this complex automation process requires 80-110 °C temperatures and 20-30 min, and consumes radiochemical yield (Figure 1a, bottom).

To simplify the azeotropic evaporation procedure, in 2010 Lemaire and co-workers introduced an innovative elution method by using phosphazenes or guanidines ( $pK_a$  value of its conjugate acid: 23-28) as additives to replace the inorganic bases classically used in the resin eluent (Figure 1b, bottom). Accordingly, an appropriate selection of solvent, protic additive, organic base, and temperature enables optimization of the reactivity of [18F]-fluoride. Later, Wester's group presented another new drying strategy known as the "Munich method" (Figure 1c, bottom). This technique consists of the elution of dry [18F]-fluoride from a strong anion exchange cartridge (SAX) with lyophilized K2.2.2/potassium hydroxide complex ( $[K^+ \subset 2.2.2]$  OH<sup>-</sup>) dissolved in anhydrous acetonitrile. These

two promising procedures are fast (3-5 min) and fully devoid of complex azeotropic drying steps, and are well-suited to an automated setup. Furthermore, these approaches should also be useful for the direct labeling of sensitive biomolecules.

Large biological molecules, such as peptides, proteins, carbohydrates, and nucleic acids, often exhibit high affinity and high specificity for many pathogenic targets. Over the past decades, <sup>18</sup>F-radiolabeled biomolecules have been the focus of research due to their potential as molecular imaging probes and therapeutic agents. When labeling large biomolecules, minimizing steric and electronic alteration to the targeting molecules is less critical than that for small organic molecules, while the use of mild and efficient labeling conditions preferably in a single step is more important. In this context, the direct incorporation of several noncarbon elements (such as silicon, aluminum, and boron) into biomolecules as fluoride-binding sites for <sup>18</sup>Fradiolabeling has attracted much attention from chemists and clinicians in the molecular imaging community. Rapid and efficient labeling approaches, based on <sup>18</sup>F-Si and <sup>18</sup>F-B bond formation, as well as <sup>18</sup>F-Al chelation scaffolding, have appeared in the literature. In this Topical Review, we will discuss the most recent strides in the field.

From the seminal reports of Schirrmacher, 8 Choudhry, 9 and Ametamey, 10 the knowledge of the silicon-fluoride acceptor (SiFA) <sup>18</sup>F-labeling strategy has increased tremendously over the past years. Simple organofluorosilanes display poor kinetic stability, and the Si-F bond is prone to dissociation in the presence of water. To shield the Si-F bond from hydrolysis, the introduction of tert-butyl groups at the silicon atom is critical for [18F]-SiFAs to achieve sufficient in vivo stability. However, the high lipophilicity of the peptide conjugates could

Received: April 4, 2015 Revised: April 18, 2015 Published: April 21, 2015

Department of Chemistry, Key Laboratory of Systems Bioengineering (the Ministry of Education), Tianjin University, and Collaborative Innovation Center of Chemical Science and Engineering, Tianjin 300072, P. R. China

<sup>&</sup>lt;sup>‡</sup>Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, P. R. China

Bioconjugate Chemistry Review





Figure 1. Production of no-carrier-added [ $^{18}$ F]-fluoride ions in an aqueous solution by proton irradiation of an [ $^{18}$ O]- $^{18}$ O] target using a medical cyclotron (top). Preparation of highly active no-carrier-added [ $^{18}$ F]-fluoride (bottom): (a) anion exchange and elution with aqueous  $K_2CO_3/K$  2.2.2 (or TNAHCO<sub>3</sub>), then azeotropic evaporation (conventional method); (b) anion exchange and elution with CH<sub>3</sub>CN solution of protic additive and organic base (Lemaire method); and (c) anion exchange and elution with anhydrous CH<sub>3</sub>CN solution of [ $K^+$ C2.2.2]OH $^-$  (Munich method).

affect its metabolism and biodistribution, generating unspecific uptake and leading to poor PET imaging quality. Several research groups have approached this problem by incorporating hydrophilic units into the SiFA-conjugated biomolecules to compensate for the high lipophilicity. For example, the group of Schirrmacher and Wängler successfully disclosed the use of aspartic acid (Asp), polyethylene glycol (PEG) spacers, and/or carbohydrates as lipophilicity-reducing auxiliaries for SiFA-peptides, hereas Ametamey and co-workers nicely introduced the tartaric acid/L-cysteic acid-containing linkers as a silicon-based alternative with counterbalanced lipophilicity. here

The [18F]-SiFA strategies can be subdivided into two labeling methods: the isotopic exchange (IE) reaction and the Si-leaving group procedure. The notable feature of the SiFA-IE labeling is that the labeling precursor and labeled radiotracer are chemically identical, eliminating the need to separate the radiotracer from its precursor. Starting from readily available [18F]F-/[18O]H2O, Wängler et al. recently developed an elegant combination of the SiFA-IE chemistry with the Munich method, providing a simple kit-production procedure for <sup>18</sup>Fradiolabeling of peptides (Figure 2, top). 16 Three general radiosynthons, including p-(di-tert-butylfluorosilyl)-benzaldehyde (SiFA-A: 1), N-succinimidyl o-(di-tert-butylfluorosilyl)benzoate (SiFB: 2), and p-(di-tert-butylfluorosilyl)benzenethiol (SiFA-SH: 3), were designed and used in the SiFA-IE chemistry (Figure 2: bottom). The SiFA-IE reaction proceeds in dipolar aprotic solvents at room temperature and below, avoiding the formation of radioactive side products during the IE. In addition to the SAX and the solid-phase extraction (SPE) cartridges, no equipment is required, thereby simplifying the entire drying and purifying procedure enormously. Moreover, the scope of this promising combination has also been extended to the labeling of proteins and affibodies. 17-19

The <sup>18</sup>F-labeling of arylfluoroborates with the nucleophilic [<sup>18</sup>F]-fluoride and near-quantitative carrier (from KHF<sub>2</sub>) to yield [<sup>18</sup>F]-organotrifluoroborates was first described by Perrin and co-workers in 2005. <sup>20</sup> The great potential advantage of this approach is that it entails only a single radioactive reaction step and is conducted in at least partially aqueous media without the need of the time-consuming azeotropic drying steps. However, this approach involves carrier <sup>19</sup>F, and the specific activity is



**Figure 2.** Labeling biomolecules through the combination of the Munich  $^{18}$ F drying method with SiFA-IE chemistry (top), and three SiFA-radiosynthons (bottom).

relatively low. In addition, HPLC purification was needed, and in one case the in vivo stability could be questioned. 21,22

Most recently, the same group developed an innovative onestep <sup>18</sup>F-labeling approach via an isotope exchange reaction on a zwitterionic ammoniomethyl-trifluoroborate (AmBF<sub>3</sub>) moiety (Figure 3).<sup>23</sup> Three simple alkylammoniomethyl-trifluoroborates (4-6) were successfully designed and employed as radiosynthons. [18F]-AMBF3 appears to be metabolically stable as the anionic BF<sub>3</sub> group is noncoordinating and bioorthogonal. For labeling, one lyophilized aliquot of AMBF<sub>3</sub>-peptides was dissolved in an acidic buffer (pH ~2.5) and transferred to the polypropylene tube into which no-carrier-added [18F]fluoride ion was eluted with saline. HPLC purification can be replaced with a simple reverse-phase Sep-Pak elution that provides radiotracer in high purity. Many peptides and proteins could be quickly labeled by this method in high radiochemical yield and at high specific activity. 24-26 For very acid-sensitive biomolecules, one-pot two-step approaches can be contemplated.

Fluoride ions are known to coordinate as ligands strongly to aluminum  $(Al^{3+})$  (>670 kJ mol<sup>-1</sup>). The first study using 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and derivatives

Bioconjugate Chemistry Review




Figure 3.  $AmBF_3$ –IE reaction for  $^{18}F$ -labeling biomolecules (top) and three  $AmBF_3$ -radiosynthons (bottom).

as chelators for  $^{18}F\text{-radiolabeling}$  biomolecules was published by McBride and co-workers in 2009.  $^{27-29}$  An aqueous solution of  $[^{18}F]F^-/[^{18}O]H_2O$  was directly mixed with AlCl $_3$  in a pH 4.0  $\pm$  0.2 optimal buffer to form the Al $^{18}F$  complex, which was moved into a solution of chelator-linked biomolecules and heated to 90–110 °C for several minutes. However, these early ligands usually suffer from the formation of unwanted hexadentate complexes with aluminum.  $^{30,31}$ 

With the identification of the pentadentate ligands (e.g., 1,4,7-triazacyclononane-1,4-diacetate motif with a methylphen-yl-acetic acid: NODA-MPAA) as improved chelators for stable Al<sup>18</sup>F chelation, the investigators found that the NODA-MPAA-containing peptides could be formulated conveniently into a lyophilized kit and radiolabeled with <sup>18</sup>F<sup>-</sup> in saline or Na<sup>18</sup>F in one step with good radiochemical yield and high specific activity (Figure 4).<sup>32–36</sup> The <sup>18</sup>F-radiolabeling products could




Figure 4. Labeling biomolecules through the formation of stable aluminum fluoride chelates.

be rapidly purified using an inexpensive and disposable Alumina-N cartridge or a reverse-phase SPE cartridge. Furthermore, excellent in vivo properties were also found for Al<sup>18</sup>F-labeled affibody molecules and proteins.

Notably, the chemists and clinicians from China and the USA presented the first clinical report on the use of a simple and one-pot lyophilized kit for Al<sup>18</sup>F-labeling PRGD2 peptide (Al<sup>18</sup>F-NOTA-PRGD2, denoted as [<sup>18</sup>F]-alfatide).<sup>37</sup> Nine patients with a primary diagnosis of lung cancer and one

tuberculosis patient were examined by using both [ $^{18}$ F]-alfatide and [ $^{18}$ F]-FDG imaging. The entire radiosynthesis and purification was finished within 20 min in 42.1  $\pm$  2.0% decay-corrected yield with >95% radiochemical purity. [ $^{18}$ F]-alfatide PET imaging identified all primary tumors, with mean standardized uptake values of 2.90  $\pm$  0.10. Tumor-to-muscle and tumor-to-blood ratios were 5.87  $\pm$  2.02 and 2.71  $\pm$  0.92, respectively.

In summary, the recently disclosed approaches by the groups of Lemaire and Wessmann represent very efficient procedures for the fast production of highly active no-carrier-added [\$^{18}F]-fluoride. On the other hand, by incorporating silicon-, boron-, and aluminum-containing prosthetic groups into biomolecules, new advances offer mild and rapid \$^{18}F-labeling approaches without HPLC purification at the radiosynthetic stage while maintaining sufficient specific activity. \$^{38} These protocols could help meet the requirements for a true kit-like \$^{18}F-labeling procedure. However, the application extension and clinical translation of these methodologies remain to be explored in more details.

### AUTHOR INFORMATION

## **Corresponding Author**

\*E-mail: majun\_an68@tju.edu.cn.

#### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

This work was supported financially by the National Natural Science Foundation of China, the National Basic Research Program of China (973 Program: 2014CB745100 and 2015CB856500), and Tianjin Municipal Science & Technology Commission (No. 14JCZDJC33400).

# REFERENCES

- (1) Cai, L., Lu, S., and Pike, V. W. (2008) Chemistry with [18F]-fluoride ion. *Eur. J. Org. Chem. 17*, 2853–2873.
- (2) Miller, P. W., Long, N. J., Vilar, R., and Gee, A. D. (2008) Synthesis of <sup>11</sup>C, <sup>18</sup>F, <sup>15</sup>O, and <sup>13</sup>N Radiolabels for Positron Emission Tomography. *Angew. Chem., Int. Ed. 47*, 8998–9033.
- (3) Jacobson, O., and Chen, X. (2010) PET designated fluoride-18 production and chemistry. *Curr. Top. Med. Chem.* 10, 1048-1059.
- (4) Pimlott, S. L., and Sutherland, A. (2011) Molecular tracers for the PET and SPECT imaging of disease. *Chem. Soc. Rev.* 40, 149–162.
- (5) Smith, G. E., Sladen, H. L., Biagini, S. C. G., and Blower, P. J. (2011) Inorganic approaches for radiolabelling biomolecules with fluorine-18 for imaging with positron emission tomography. *Dalton Trans.* 40, 6196–6205.
- (6) Lemaire, C. F., Aerts, J. J., Voccia, S., Libert, L. C., Mercier, F., Goblet, D., Plenevaux, A. R., and Luxen, A. J. (2010) Fast production of highly reactive no-carrier-added [18F]fluoride for the labeling of radiopharmaceuticals. *Angew. Chem., Int. Ed.* 49, 3161–3164.
- (7) Wessmann, S. H., Henriksen, G., and Wester, H.-J. (2012) Cryptate mediated nucleophilic <sup>18</sup>F-fluorination without azeotropic drying. *NuklearMedizin* 51, 1–8.
- (8) Schirrmacher, R., Bradtmöller, G., Schirrmacher, E., Thews, O., Tillmanns, J., Siessmeier, T., Buchholz, H. G., Bartenstein, P., Wängler, B., Niemeyer, C. M., et al. (2006) <sup>18</sup>F-Labeling of peptides by means of an organosilicon-based fluoride acceptor. *Angew. Chem., Int. Ed.* 45, 6047–6050.
- (9) Choudhry, U., Martin, K. E., Biagini, S., and Blower, P. J. (2006) Alkoxysilane groups for instant labeling of biomolecules with <sup>18</sup>F. *Nucl. Med. Commun.* 27, 293.
- (10) Mu, L., Hhne, A., Schubiger, P. A., Ametamey, S. M., Graham, K., Cyr, J. E., Dinkelborg, L., Stellfeld, T., Srinivasan, A., Voigtmann,

Bioconjugate Chemistry Review

U., et al. (2008) Silicon-based building blocks for one-step <sup>18</sup>Fradiolabeling of peptides for PET imaging. *Angew. Chem., Int. Ed.* 47, 4922–4925.

- (11) Wängler, C., Waser, B., Alke, A., Iovkova, L., Buchholz, H.-G., Niedermoser, S., Jurkschat, K., Fottner, C., Bartenstein, P., Schirrmacher, R., et al. (2010) One-step <sup>18</sup>F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): *in vitro* and *in vivo* evaluation as tumor imaging agents for positron emission tomography (PET). *Bioconjugate Chem.* 21, 2289–2296.
- (12) Amigues, E., Schulz, J., Szlosek-Pinaud, M., Fernandez, P., Silvente-Poirot, S., Brillouet, S., Courbon, F., and Fouquet, E. (2012) [ $^{18}$ F]Si-RiboRGD: from design and synthesis to the imaging of  $\alpha\nu\beta$ 3 integrins in melanoma tumors. *ChemPlusChem 77*, 345–349.
- (13) Lindner, S., Michler, C., Leidner, S., Rensch, C., Wängler, C., Schirrmacher, R., Bartenstein, P., and Wängler, B. (2014) Synthesis and *in vitro* and *in vivo* evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography. *Bioconjugate Chem.* 25, 738–749.
- (14) Kostikov, A. P., Chin, J., Orchowski, K., Niedermoser, S., Kovacevic, M. M., Aliaga, A., Jurkschat, K., Wängler, B., Wängler, C., Wester, H.-J., et al. (2012) Oxalic acid supported Si-<sup>18</sup>F-radio-fluorination: one-step radiosynthesis of N-succinimidyl 3-(di-tert-butyl[<sup>18</sup>F]fluorosilyl) benzoate ([<sup>18</sup>F]SiFB) for protein labeling. *Bioconjugate Chem.* 23, 106–114.
- (15) Dialer, L. O., Selivanova, S. V., Müller, C. J., Müller, A., Stellfeld, T., Graham, K., Dinkelborg, L. M., Krämer, S. D., Schibli, R., Reiher, M., et al. (2013) Studies toward the development of new siliconcontaining building blocks for the direct <sup>18</sup>F-labeling of peptides. *J. Med. Chem.* 56, 7552–7563.
- (16) Wängler, C., Niedermoser, S., Chin, J., Orchowski, K., Schirrmacher, E., Jurkschat, K., Iovkova-Berends, L., Kostikov, A. P., Schirrmacher, R., and Wängler, B. (2012) One-step <sup>18</sup>F-labeling of peptides for positron emission tomography imaging using the SiFA methodology. *Nat. Protoc.* 7, 1946–1955.
- (17) Kostikov, A. P., Chin, J., Orchowski, K., Schirrmacher, E., Niedermoser, S., Jurkschat, K., Iovkova-Berends, L., Wängler, C., Wängler, B., and Schirrmacher, R. (2012) Synthesis of [<sup>18</sup>F]SiFB: a prosthetic group for direct protein radiolabeling for application in positron emission tomography. *Nat. Protoc.* 7, 1956–1963.
- (18) Wängler, B., Kostikov, A. P., Niedermoser, S., Chin, J., Orchowski, K., Schirrmacher, E., Iovkova-Berends, L., Jurkschat, K., Wängler, C., and Schirrmacher, R. (2012) Protein labeling with the labeling precursor [18F]SiFA-SH for positron emission tomography. *Nat. Protoc.* 7, 1964–1969.
- (19) Glaser, M., Iveson, P., Hoppmann, S., Indrevoll, B., Wilson, A., Arukwe, J., Danikas, A., Bhalla, R., and Hiscock, D. (2013) Three methods for  $^{18}$ F labeling of the HER2-binding affibody molecule  $Z_{\rm HER2,2891}$  including preclinical assessment. *J. Nucl. Med.* 54, 1981–1988.
- (20) Ting, R., Adam, M. J., Ruth, T. J., and Perrin, D. M. (2005) Arylfluoroborates and alkylfluorosilicates as potential PET imaging agents: high-yielding aqueous biomolecular <sup>18</sup>F-labeling. *J. Am. Chem. Soc. 127*, 13094–13095.
- (21) Ting, R., Harwig, C., auf dem Keller, U., McCormick, S., Austin, P., Overall, C. M., Adam, M. J., Ruth, T. J., and Perrin, D. M. (2008) Toward [18F]-labeled aryltrifluoroborate radiotracers: in vivo positron emission tomography imaging of stable aryltrifluoroborate clearance in mice. *J. Am. Chem. Soc.* 130, 12045–12055.
- (22) Li, Y., Liu, Z., Pourghiasian, M., Lin, K.-S., Schaffer, P., Benard, F., and Perrin, D. M. (2013) Alkyne-<sup>18</sup>F-ArBF<sub>3</sub> for one-pot click <sup>18</sup>F-labeling of bombesin for in vivo PET imaging of tumors expressing the GRP-receptor. *Am. J. Nucl. Med. Mol. Imaging* 3, 57–70.
- (23) Liu, Z., Pourghiasian, M., Radtke, M. A., Lau, J., Pan, J., Dias, G. M., Yapp, D., Lin, K.-S., Bénard, F., and Perrin, D. M. (2014) An organotrifluoroborate for broadly applicable one-step <sup>18</sup>F-labeling. *Angew. Chem., Int. Ed.* 53, 11876–11880.
- (24) Liu, Z., Radtke, M., Wong, M., Lin, K.-S., Yapp, D., and Perrin, D. M. (2014) Dual mode fluorescent <sup>18</sup>F-PET tracers: efficient

- modular synthesis of rhodamine-[cRGD]<sub>2</sub>-[<sup>18</sup>F]-organotrifluoroborate, rapid and high yielding <sup>18</sup>F-labeling at high specific activity, and correlated in vivo PET imaging and ex vivo fluorescence. *Bioconjugate Chem.* 25, 1951–1962.
- (25) Liu, Z., Pourghiasian, M., Benard, F., Pan, J., Lin, K.-S., and Perrin, D. M. (2014) Preclinical evaluation of a high affinity <sup>18</sup>F-trifluoroborate octreotate derivative for somatostatin receptor imaging. *J. Nucl. Med.* 55, 1499–1505.
- (26) Liu, Z., Amouroux, G., Zhang, Z., Pan, J., Hundal-Jabal, N., Colpo, N., Lau, J., Perrin, D. M., Bénard, F., and Lin, K.-S. (2015) <sup>18</sup>F-trifluoroborate derivatives of [Des-Arg<sup>10</sup>]Kallidin for imaging bradykinin B1 receptor expression with positron emission tomography. *Mol. Pharmaceutics* 12, 974–982.
- (27) McBride, W. J., Sharkey, R. M., Karacay, H., D'Souza, C. A., Rossi, E. A., Laverman, P., Chang, C. H., Boerman, O. C., and Goldenberg, D. M. (2009) A novel method of <sup>18</sup>F radiolabeling for PET. *J. Nucl. Med.* 50, 991–998.
- (28) Laverman, P., McBride, W. J., Sharkey, R. M., Eek, A., Joosten, L., Oyen, W. J. G., Goldenberg, D. M., and Boerman, O. C. (2010) A novel facile method of labeling octreotide with <sup>18</sup>F-fluorine. *J. Nucl. Med.* 51, 454–461.
- (29) McBride, W. J., D'Souza, C. A., Sharkey, R. M., Sharkey, R. M., Karacay, H., Rossi, E. A., Chang, C.-H., and Goldenberg, D. M. (2010) Improved <sup>18</sup>F labeling of peptides with a fluoride-aluminum-chelate complex. *Bioconjugate Chem.* 21, 1331–1340.
- (30) D'Souza, C. A., McBride, W. J., Sharkey, R. M., Todaro, L. J., and Goldenberg, D. M. (2011) High-yielding aqueous <sup>18</sup>F-labeling of peptides via Al<sup>18</sup>F chelation. *Bioconjugate Chem.* 22, 1793–1803.
- (31) Shetty, D., Choi, S. Y., Jeong, J. M., Lee, J. Y., Hoigebazar, L., Lee, Y. S., Lee, D. S., Chung, J. K., Lee, M. C., and Chung, Y. K. (2011) Stable aluminium fluoride chelates with triazacyclononane derivatives proved by X-ray crystallography and F-labeling study. *Chem. Commun.* 47, 9732–9734.
- (32) McBride, W. J., D'Souza, C. A., Karacay, H., Sharkey, R. M., and Goldenberg, D. M. (2012) New lyophilized kit for rapid radio-fluorination of peptides. *Bioconjugate Chem.* 23, 538–547.
- (33) Heskamp, S., Laverman, P., Rosik, D., Boschetti, F., van der Graaf, W. T., Oyen, W. J., van Laarhoven, H. W., Tolmachev, V., and Boerman, O. C. (2012) Imaging of human epidermal growth factor receptor type 2 expression with <sup>18</sup>F-labeled affibody molecule Z<sub>HER2:2395</sub> in a mouse model for ovarian cancer. *J. Nucl. Med.* 53, 146–153.
- (34) Laverman, P., D'Souza, C. A., Eek, A., McBride, W. J., Sharkey, R. M., Oyen, W. J., Goldenberg, D. M., and Boerman, O. C. (2012) Optimized labeling of NOTA-conjugated octreotide with F-18. *Tumour Biol.* 33, 427–434.
- (35) Dijkgraaf, I., Franssen, G. M., McBride, W. J., D'Souza, C. A., Laverman, P., Smith, C. J., Goldenberg, D. M., Oyen, W. J., and Boerman, O. C. (2012) PET of tumors expressing gastrin-releasing peptide receptor with an <sup>18</sup>F-labeled bombesin analog. *J. Nucl. Med.* 53, 947–952.
- (36) Dijkgraaf, I., Terry, S. Y. A., McBride, W. J., Goldenberg, D. M., Laverman, P., Franssen, G. M., Oyen, W. J., and Boerman, O. C. (2013) Imaging integrin alpha-v-beta-3 expression in tumors with an <sup>18</sup>F-labeled dimeric RGD peptide. *Contrast Media Mol. Imaging* 8, 238–245
- (37) Wan, W., Guo, N., Pan, D., Yu, C., Weng, Y., Luo, S., Ding, H., Xu, Y., Wang, L., Lang, L., et al. (2013) First experience of <sup>18</sup>F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. *J. Nucl. Med.* 54, 691–698.
- (38) During our preparation of this Topical Review, another interesting review about Fluorine-18 Radiochemistry was published, see: Jacobson, O., Kiesewetter, D. O., and Chen, X. (2015) Fluorine-18 radiochemistry, labeling strategies and synthetic routes. *Bioconjugate Chem.* 26, 1–18.